11:30 AM EST - Abattis Bioceuticals Corp. : Announced that they have signed a letter of intent with Blockstrain Technology Corp. to integrate BLOCKStrain's proprietary technology into Abattis's product and services ecosystem. Through their collaboration, the parties hope to enable Abattis clients to instantly arrange for sales, shipping, testing and analysis of Abattis products and give clients comprehensive visibility over such products over their entire lifecycles. Abattis and BLOCKStrain also intend to explore development and integration opportunities to expand on Abattis's current life sciences and biotechnology services offerings. Pursuant to the LOI, Abattis and BLOCKStrain have agreed to negotiate in good faith the terms of a definitive technology development agreement respecting the terms of their partnership. Abattis Bioceuticals Corp.
shares ATT:CNX are trading off 2.78 percent at $0.18.
